Business Wire

NEUSTAR

Share
Neustar: New Ponemon Institute Report highlights value of threat data feeds in improving organisations’ security posture

Threat data feeds can help organisations strengthen their cybersecurity posture, according to a new report from Ponemon Institute, the pre-eminent research centre dedicated to privacy, data protection and information security policy. Neustar Inc. , a global information services and technology company and leader in identity resolution, sponsored the independently conducted study on the state of threat feed effectiveness in the United States and the United Kingdom.

As cyberthreats proliferate, many organisations are using threat feeds with insights from domain name system (DNS) data to help IT security teams better understand threats and block malicious activity. A large majority (79%) of the more than 1,000 security professionals participating in the Ponemon study said threat data feeds were essential to their organisation’s ability to achieve a strong cybersecurity posture, and more than half (55%) rate the quality of their threat feeds’ ability to pinpoint cyberthreats as very high.

Study participants said threat data feeds offer a number of benefits: they add unique data to better inform security (71%), increase preventive blocking to ensure a better defence (63%), reduce the mean time to detect and remediate an attack (55%), and reduce the time spent researching false positives (51%).

However, more than half (56%) of respondents also said threat feeds deliver data that is often too voluminous and/or complex to provide timely and actionable intelligence.

Neustar’s UltraThreat Feeds service addresses these issues by drawing on proprietary data derived from the company’s expansive authoritative and recursive DNS services, DDoS mitigation solutions, OneID system and IP geolocation data. This service, which processes the data and outputs the observations and key insights, has been designed by Neustar’s renowned DNS experts, as well as leading academic researchers. UltraThreat Feeds data, provided as either near real-time threat data feeds or via API calls (JSON format), enable organisations to detect potential threats and identify and stop bad traffic, both inbound and outbound.

“Facing an increase in the volume, sophistication and diversity of threats, enterprises are investing significant resources into threat intelligence solutions to bolster their cyber defences,” said Michael Kaczmarek, senior vice president at Neustar. “Solutions that deliver real-time information on active threats, like Neustar’s UltraThreat Feeds service, can quickly deliver ROI across many layers of an organisation’s defence by improving the performance of network and application security tools – such as SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls – which require threat data to effectively detect and block malicious actors.”

Each of the organisations surveyed by Ponemon faced an average of 28 cyberattacks in the past two years. On average, respondents said 38% of these cyberattacks were not stopped because security teams lacked timely and actionable data from their data feeds. Respondents also reported that half (50%) of all attacks can be stopped using timely and actionable intelligence from their threat feeds.

“The deep, rich threat data delivered by Neustar’s UltraThreat Feeds service empowers users to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks,” added Kaczmarek.

The Ponemon report is based on survey responses from 1,025 IT security practitioners (70% of whom were at or above the supervisory level) in the U.S. and the U.K. whose organisations use threat data in their cybersecurity programmes or infrastructure. The most-represented industry was financial services (18% of respondents), followed by industrial and manufacturing (12%), retail (11%), public sector (11%), and health and pharmaceuticals (9%). Just over half of the participants were from organisations with a global headcount of more than 5,000 employees. The surveys were carried out in November 2020.

To access the full report, go to https://www.home.neustar/resources/whitepapers/state-of-threat-feed-effectiveness .

For more information about Neustar’s UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultrathreat-feeds . To learn more about Neustar’s full suite of security solutions, visit https://www.home.neustar/security-solutions .

-ENDS-

About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enable trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in marketing, risk, communications and security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release

Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye